Biora Therapeutics, Inc. Common Stock
BIOR
BIOR was delisted on the 10th of December, 2024.
47 hedge funds and large institutions have $206M invested in Biora Therapeutics, Inc. Common Stock in 2021 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 21 increasing their positions, 10 reducing their positions, and 11 closing their positions.
958% more call options, than puts
Call options by funds: $275K | Put options by funds: $26K
110% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 10
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
3% more capital invested
Capital invested by funds: $199M → $206M (+$6.81M)
9% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 11
2% less funds holding
Funds holding: 48 → 47 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$14.5M |
| 2 |
ACM
Altium Capital Management
New York
|
+$9.64M |
| 3 |
BlackRock
New York
|
+$2.96M |
| 4 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$1.97M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$1.19M |
| 2 |
Wells Fargo
San Francisco,
California
|
-$443K |
| 3 |
D.E. Shaw & Co
New York
|
-$235K |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$223K |
| 5 |
DCM
Dupont Capital Management
Wilmington,
Delaware
|
-$184K |
BIOR Hedge Fund Activity: Q1 2021 in Review
47 of the 5,696 institutional investors tracked by Wall St. Rank reported a position in Biora Therapeutics, Inc. Common Stock (BIOR) for Q1 2021, worth a combined $206M — up 3.4% from $199M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of BIOR and 10 opened new positions — a net loss of 1 holder — while 10 trimmed existing stakes and 21 added.
The largest buyer was Armistice Capital, opening a new position worth an estimated $14.5M. The largest seller was Point72 Asset Management, exiting entirely with an estimated $1.19M sold.
- 47 institutional investors held Biora Therapeutics, Inc. Common Stock (BIOR) as of Q1 2021, down from 48 in Q4 2020.
- Funds reported $206M of Biora Therapeutics, Inc. Common Stock stock for Q1 2021, up 3.4% quarter-over-quarter.
- 10 funds opened new Biora Therapeutics, Inc. Common Stock positions in Q1 2021 and 11 closed out, a net change of -1 holder.
- The largest Biora Therapeutics, Inc. Common Stock buyer in Q1 2021 was Armistice Capital, an estimated $14.5M added.
- The largest Biora Therapeutics, Inc. Common Stock seller in Q1 2021 was Point72 Asset Management, an estimated $1.19M sold.
Based on aggregated 13F filings for Q1 2021.